Menlo Therapeutics, a late stage biopharmaceutical company, completed its merger with Foamix Pharmaceuticals, a clinical stage specialty pharmaceutical company. The transaction is structured as a stock-for-stock exchange. Under the terms of the merger agreement, each share of Foamix stock was exchanged for 0.5924 of a share of Menlo common stock and a contingent stock right. "This is an exciting day as we take a significant step toward becoming a broad dermatology franchise. The combined company already has an approved, commercial-stage product, AMZEEQ™, and several late-stage product candidates with several meaningful near-term catalysts. I am excited about the opportunities ahead for the combined company as we work towards improving the lives of patients with a differentiated and innovative product pipeline," David Domzalski, Menlo CEO.